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non-vitamin K antagonist oral anticoagulants (NOACs) screened for
the presence of liver ﬁbrosis (LF) and followed to record the
occurrence of bleeding and cardiovascular events (CVEs). A
detailed description of major and minor bleedings is provided
according to anticoagulant treatment (VKAs vs. NOACs) and to the
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D. Pastori et al. / Data in Brief 17 (2018) 830–836 831bleeding in patients with atrial ﬁbrillation and advanced liver
ﬁbrosis on treatment with vitamin K or non-vitamin K antagonists
oral anticoagulants” (Pastori et al., 2018) [1].
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Medicine
ore speciﬁc sub-
ject areaCardiologyype of data Tables and Figures
ow data was
acquiredPost-hoc analysis of a prospective cohort of AF patients treated with oral
anticoagulantsata format Analyzed (Cox regression analysis and Kaplan-Meier survival analysis results)
xperimental
factorsThe relationship between liver ﬁbrosis and bleeding events in Af patients on
anticoagulantsxperimental
featuresLiver ﬁbrosis deﬁned by FIB-4 score 4 3.25.ata source
locationMulticenter study. Patients were recruited from Sapienza University of Rome,
Rome, Italy; University Magna Græcia of Catanzaro, Catanzaro, Italy; University
of Florence, Florence, Italy.ata accessibility The data are accessible within the article
elated research
article“Incidence of bleeding in patients with atrial ﬁbrillation and advanced liver
ﬁbrosis on treatment with vitamin K or non-vitamin K antagonist oral antic-
oagulants” (Pastori et al., 2018 in press) [1]Value of the data
 Data presented here provide information about the characteristics of patients treated with VKAs or
NOACs.
 Data here presented provide a detailed description of bleeding events according to the presence of
liver ﬁbrosis.
 These data for the subgroup analysis on the different risk of CVEs in patients treated with VKAs or
NOACs.1. Data
The data presented include clinical and biochemical characteristics of atrial ﬁbrillation (AF)
patients treated with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs)
(Table 1). Table 2 reports characteristics of patients experiencing or not a bleeding event.
A detailed description of major and minor bleedings according to anticoagulant treatment (VKAs
vs. NOACs) is reported in Table 3. Table 4 reports major bleedings according to the presence of LF
(deﬁned by a FIB-4 score 4 3.25) in the all cohort.
Survival analysis showed that in VKA-treated patients with high FIB-4, a higher incidence of
cardiovascular events (CVEs) compared to those with normal FIB-4 (2.1% vs. 9.8%, log-rank test p ¼
0.005) was found (Fig. 1). In the NOAC group, a similar rate of CVEs was observed between the two
groups (5.8% vs 3.0% in patients with and without high FIB-4, log-rank test, p ¼ 0.279, Fig. 2).
Table 2
Clinical characteristics of patients with and without bleeding events.
Any bleeding p Value
No (n ¼ 1973) Yes (n ¼ 357)
Age (years) 74.5 7 9.5 75.6 7 8.0 0.019
NOAC treatment (vs. VKA) (%) 47.5 26.9 o 0.001
Women (%) 46.5 42.9 0.205
Current cigarette smokers (%) 13.1 14.2 0.551
Persistent/permanent atrial ﬁbrillation (%) 64.4 62.0 0.399
HAS-BLED score 1.7 7 0.9 1.9 7 0.9 o 0.001
CHA2DS2-VASc score 3.1 7 1.5 3.3 7 1.4 0.042
Arterial Hypertension (%) 86.0 87.7 0.452
Diabetes mellitus (%) 24.1 20.4 0.136
Heart failure (%) 15.0 14.1 0.745
Previous cerebrovascular events (%) 15.5 15.1 0.937
Previous cardiac events (%) 17.4 22.8 0.017
Anti-platelet drugs (%) 11.0 11.8 0.647
Statins (%) 40.8 41.9 0.725
Time in therapeutic range (%)a 59.9 7 22.9 60.6 7 19.7 0.606
AST (U/l) 23.2 7 11.2 22.9 7 11.2 0.730
ALT (U/l) 24.2 7 14.6 23.013.3 7 0.130
Haemoglobin (g/dl) 13.4 7 1.6 13.5 7 1.7 0.591
Platelet count (*109/L) 226.7 7 66.9 223.4 7 68.9 0.395
a Only for VKA-treated patients.
Table 1
Characteristics of patients treated with VKAs or NOACs.
VKAs (n ¼ 1297) NOACs (n ¼ 1033) p Value
Age (years) 72.7 7 8.9 77.1 7 9.1 o 0.001
Women (%) 44.1 48.3 0.045
Current cigarette smokers (%) 16.0 9.6 o 0.001
Persistent/permanent atrial ﬁbrillation (%) 66.4 60.8 0.007
HAS-BLED score 1.8 7 1.0 1.5 7 0.8 o 0.001
CHA2DS2-VASc score 3.0 7 1.5 3.4 7 1.4 o 0.001
Arterial Hypertension (%) 84.2 88.9 0.001
Diabetes mellitus (%) 22.7 24.6 0.301
Heart failure (%) 12.7 17.5 0.001
Previous cerebrovascular events (%) 13.2 18.3 0.001
Previous cardiac events (%) 17.7 18.8 0.515
Anti-platelet drugs (%) 11.3 10.8 0.739
Statins (%) 39.2 43.3 0.050
AST (U/l) 23.6 7 12.0 22.5 7 10.0 0.011
ALT (U/l) 24.9 7 15.2 22.9 7 13.4 0.001
Haemoglobin (g/dl) 13.5 7 1.6 13.4 7 1.6 0.036
Platelet count (*109/L) 229.4 7 72.8 222.2 7 59.4 0.009
FIB-4 index 1.7 7 1.0 1.8 7 0.8 0.105
D. Pastori et al. / Data in Brief 17 (2018) 830–8368322. Experimental design, materials, and methods
We performed a post-hoc analysis of a prospective multicentre observational cohort study
including 2330 AF patients treated with VKAs (n ¼ 1297) or NOACs (n ¼ 1033). All patients treated
with VKAs (warfarin or acenocoumarol) were locally monitored in specialized anticoagulation clinics
for INR determination and VKA prescription. None of the patients measured INRs at home (i.e. with
point of care devices) and time in therapeutic range (TTR) was used to assess the quality of antic-
oagulation according to the linear interpolation method described by Rosendaal et al. [2]. NOACs were
Table 3
Description of major and minor bleeding events according to anticoagulant treatment.
Whole cohort (n ¼ 2330) VKAs (n ¼ 1297) NOACs (n ¼ 1033)
Major bleedings
Cerebral/Subdural (n) 18 14 4
Gastrointestinal (n) 20 10 10
Muscular (n) 11 11 0
Articular (n) 10 9 1
Haematuria (n) 9 8 1
Epistaxis with fall in Hb (n) 5 5 0
Extended hematoma (n) 4 3 1
Respiratory (n) 2 2 0
Retroperitoneal (n) 2 2 0
Ocular (n) 14 13 1
Pericardial (n) 1 1 0
Metrorrhagia (n) 1 1 0
Decrease of Hb Z 2 gr/dl (n) 23 1 22
Total (n) 120 (5.1%) 80 (6.2%) 40 (3.9%)
Minor bleedings
Epistaxis (n) 65 56 9
Gastrointestinal (n) 52 34 18
Conjunctival (n) 35 33 2
Haematuria (n) 38 24 14
Cutaneous (n) 19 16 3
Post-intervention (n) 6 4 2
Oral (n) 10 9 1
Respiratory (n) 5 2 3
Ear (n) 2 2 0
Metrorrhagia (n) 1 1 0
Decrease of Hb o 2 gr/dl (n) 4 0 4
Total (n) 237 (10.2%) 181 (13.9%) 56 (5.4%)
Table 4
Major bleedings according to the presence of liver ﬁbrosis in the all cohort.
FIB-4 4 3.25 (n ¼ 129) FIB-4 r 3.25 (n ¼ 2201)
Cerebral/Subdural (n) 4 (3.1%) 14 (0.6%)
Gastrointestinal (n) 3 (2.3%) 17 (0.8%)
Muscular (n) 0 (0%) 11 (0.5%)
Articular (n) 0 (0%) 10 (0,4%)
Haematuria (n) 1 (0.8%) 8 (0.4%)
Epistaxis with fall in Hb (n) 2 (1.5%) 3 (0.1%)
Extended hematoma (n) 0 (0%) 1 (0.04%)
Respiratory (n) 0 (0%) 2 (0.08%)
Retroperitoneal (n) 0 (0%) 2 (0.08%)
Ocular (n) 2 (1.5%) 12 (0.5%)
Pericardial (n) 0 (0%) 1 (0.04%)
Metrorrhagia (n) 0 (0%) 1 (0.04%)
Decrease of Hb Z 2 gr/dl (n) 0 (0%) 23 (1.0%)
Cerebral/Subdural (n) 12 (9.3%) 108 (4.9%)
D. Pastori et al. / Data in Brief 17 (2018) 830–836 833prescribed according to the regulatory Italian Agency of Drugs (AIFA) indications and European
Society of Cardiology (ESC) guidelines [3].
Exclusion criteria were: prosthetic heart valves, cardiac revascularization in the previous year,
severe cognitive impairment, chronic autoimmune systemic diseases, and active cancer. Patients
treated with antiplatelet drugs alone were also excluded. At baseline, information about personal
medical history and concomitant medications were collected, and HAS-BLED (the labile INR was
Fig. 1. Incidence of CVEs in AF patients treated with VKAs according to FIB-4 value (2.1% vs. 9.8% in patients with and without
high FIB-4, log-rank test p ¼ 0.005).
Fig. 2. Incidence of CVEs in AF patients treated with NOACs according to FIB-4 value (5.8% vs 3.0% in patients with and without
high FIB-4, log-rank test, p ¼ 0.279).
D. Pastori et al. / Data in Brief 17 (2018) 830–836834scored 0 in NOAC users). and CHA2DS2-VASc scores were calculated. Cardiovascular risk factors, such
as arterial hypertension [4], type 2 diabetes mellitus [5] and heart failure [6] were deﬁned according
to international guidelines. Patients underwent routine laboratory analyses including AST (U/l), ALT
(U/l), haemoglobin (g/dl) and platelet count (× 109/L).
D. Pastori et al. / Data in Brief 17 (2018) 830–836 835The presence of signiﬁcant LF was assessed non-invasively by FIB-4 in all patients; FIB-4 was
calculated according Sterling et al. by the formula: age (years) × AST (U/L)/PLT (109/L) × ALT (U/L)1/2. A
value of FIB-4 4 3.25 was set as cut-off for LF [7]. FIB-4 has been validated in different settings of
CLD, such viral and metabolic liver disease [8,9].2.1. Study primary endpoint
Bleeding events were classiﬁed according to the International Society on Thrombosis and
Hemostasis (ISTH) [10]. Major bleeding was deﬁned as fatal bleeding, symptomatic bleeding in a
critical area or organ, i.e. intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, peri-
cardial or intramuscular with compartment syndrome; bleeding causing a fall in haemoglobin level of
2 g/dl or more or leading to transfusion of two or more units of whole blood or red blood cells. All
cases of clinically relevant bleeding events that were not classiﬁed as major were considered as minor.2.2. Study secondary endpoint
The secondary endpoint was a composite of CVEs including fatal/non-fatal myocardial infarction
(MI) or ischemic stroke, cardiac revascularization (stent placement or coronary artery bypass graft),
cardiovascular death, transient ischemic attack (TIA) and systemic embolism. Diagnosis of MI was
made according to the third universal deﬁnition [11]. The occurrence of ischemic stroke was deter-
mined on clinical manifestations and conﬁrmed by computed tomography or magnetic resonance;
TIA was deﬁned according to the Classiﬁcation of Cerebrovascular Diseases III [12]. If a patient died
within 4 weeks of myocardial infarction or ischemic stroke, these events were recorded as fatal
myocardial infarction or ischemic stroke, respectively. Systemic embolism was deﬁned as an acute
occlusion of a vessel of an extremity or organ, documented by imaging, surgery, or autopsy ﬁndings.
Death was classiﬁed as cardiovascular unless an unequivocal non-cardiovascular cause of death was
identiﬁed. Cardiovascular death included sudden death, progressive congestive HF, and procedure-
related death.2.3. Statistical analysis
Categorical variables were reported as counts (percentages). The normal distribution of para-
meters was assessed by Kolmogorov–Smirnov test. Continuous variables were expressed as mean 7
standard deviation, or median and interquartile range. Independence of categorical variables was
tested with the χ2 test. Student t test for unpaired samples was used to compare means.
The cumulative incidence of bleedings and CVEs were estimated using a Kaplan–Meier product-
limit estimator. Survival curves were formally compared using the log-rank test. Cox proportional
hazards analyses were used to calculate the adjusted relative hazard ratio (HR) by each clinical
variable. Due to a signiﬁcant difference in the length of follow-up, a separate survival analysis was
performed according to the use of VKAs or NOACs, respectively. Covariates used as candidates for
multivariable models included: low TTR (o 70%, only for VKA patients), age, sex, current cigarette
smoking, arterial hypertension, diabetes, high FIB-4 (4 3.25), previous cardiac events, previous
cardiovascular events, heart failure, haemoglobin, antiplatelet drugs and statins. The ﬁnal multi-
variable model was chosen through forward stepwise selection.
Statistical signiﬁcance was set at a p value o 0.05. All tests were two-tailed and analyses were
performed using computer software packages (SPSS-18.0, SPSS Inc.).Acknowledgments
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